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Results
To the best of our knowledge, 10 cases (6 men, 4 women; mean 
age 44.5 years, range 22–59) have been reported since 2012. The 
main characteristics are summarized in Table 1. Six patients re-
ceived a combination of BRAF inhibitor (BRAFi) associated with a 
MEK inhibitor (MEKi), 2 patients a PD-1/PD-L1 inhibitor (PD-1i/
PD-L1i) and 2 patients a CTLA-4 inhibitor (CTLA-4i), including 
one in combination with a PD-1i. We found that the clinical pre-
sentation was different according to culprit drugs. Tattoo eruption 
associated with BRAFi + MEKi presented mostly as a complete in-
filtration/induration of dark-colored tattoos with striking inflam-
matory borders in 5 out of 6 cases [10–13, 16]. Tattoo reactions with 
CTLA-4i or PD-1i/PD-L1i were reminiscent of what is usually ob-
served with sarcoidosis or granulomatous tattoo reactions in gen-
eral, e.g. papules and nodules scattered within black tattoos [8, 9, 
14, 15]. Tattoos were dark/black in 86% (6/7) of the cases. In case 
of multicolored tattoos, other colors were spared. Delays of onset 
after the first cycle were as follows from the earliest to the latest: 
CTLA-4i + PD-1i (2 months) > BRAFi + MEKi (2–6 months) > 
PD-1i/PD-L1i (9–15 months). Only 1 patient had additional cuta-
neous sarcoids on plain skin and erythema nodosum [9]. Biopsies 
showed noncaseating granulomas in 67% (6/9), including all the 
cases with CTLA-4i and/or PD-1i/PD-L1i. In the 3 remaining cas-
es, there was only a lymphocytic infiltration without any granulo-
mas [10, 12, 13]. Angiotensin-converting enzyme was elevated in 2 
cases of granulomatous reactions [9, 15]. Lung involvement and 
lymph nodes were reported in 60% (6/10). Management was high-
ly variable according to authors. It included local corticosteroids, 
combination of local and systemic corticosteroids, abstention with 
either maintenance or discontinuation of the treatment, and switch 
to PD-1i or surgery. One patient experienced relapses with BRAFi 
+ MEKi cycles [10]. Overall, outcome was always favorable.
Discussion
Granulomatous eruptions under ICPIs are an uncommon im-
mune-related adverse event that can become more and more fre-
quently encountered with the increased use of this therapeutic 
class [7]. All the patients under PD-1i/PD-L1i/CTLA-4i developed 
sarcoid-like reactions on tattoos. Delays of onset and outcomes 
were here in line with what is known from the literature [7]. On 
the other hand, cutaneous granulomatous reactions and sarcoid-
osis are rather infrequent with BRAFi [17]. Out of the 5 patients 
under BRAFi + MEKi with available biopsies, 3 displayed a lym-
phocytic infiltration in the dermis without granulomas. Besides, 
the clinical presentation was rather different with a marked ery-
thema around the tattoos which is totally unusual compared to the 
usual tattoo granulomatous reactions we often see in practice [4, 
18, 19]. Only 1 patient did not present such an inflammatory reac-
tion around the affected tattoos [16]. To date, there is no case re-
port of tattoo reaction with BRAFi alone. In 1 patient [11], the 
reaction developed 3 months after MEKi introduction. The differ-
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Introduction
Cutaneous reactions on permanent tattoos have been reported 
in the past during immune restauration syndrome under highly 
active antiretroviral therapy for human immunodeficiency virus 
[1, 2] as well as during interferon therapy for hepatitis C with the 
induction of sarcoidosis [3, 4]. Besides, anecdotal cases of granu-
lomatous tattoo reaction under tumor necrosis factor α inhibitors 
have been reported [5]. Inhibitors of the mitogen-activated protein 
(MAP) kinase pathway and immune checkpoint inhibitors (ICPIs) 
are widely used now in the management of advanced malignancies. 
However, ICPIs are associated with a wide range of dermatologic 
manifestations including sarcoidosis [6] and granulomatous reac-
tions [7]. With the increased popularity of tattoos worldwide, cas-
es of tattoo reactions are slowly increasing. We reviewed here all 
the case reports of tattoo reactions associated with targeted thera-
pies and ICPIs.
Materials and Methods
We performed a review of the existing English- and French-
language literature on patients who developed a reaction on ≥1 
tattoo during or after targeted therapies and ICPIs. The databases 
MEDLINE (1946–2019) and Scopus (1823–2019) were initially 
searched on June 6, 2019. The following keywords were used: tat-
too, tattoos, tattooing, molecular targeted therapies, BRAF inhibi-
tor; MEK inhibitor; immune checkpoint inhibitor; as well as the 
following molecules: avelumab, nivolumab, pembrolizumab; ipili-
mumab; dabrafenib, encorafenib, vemurafenib; binimetinib, cobi-
metinib, trametinib. All the articles reporting on ≥1 case(s) of tar-
geted therapies/ICPI-associated tattoo reactions were included. 
We also included conference abstracts if relevant. 
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ences observed in histology may be related to sampling, and re-
peated biopsies could disclose genuine granulomas. Another hy-
pothesis is that those reactions belong to different parts of the same 
spectrum of cutaneous immune-related adverse events.
The physiopathogeny of granuloma formation under ICPIs 
may be related to the activation of the innate immune system, the 
dysfunction of regulatory T cells and the expansion of Th7 cells. 
Reduction of CTLA-4 expression may contribute to increased pro-
liferation capacity [7]. On the other side, the inhibition of BRAF 
and MEK could lead to a paradoxical activation of ERK as report-
ed recently [20]. Besides, the inhibition of MEK, which is a negative 
regulator of AKT [21], could lead to a possible activation of the 
AKT/mTOR pathway, which could induce the formation of gran-
ulomas [22]. This review is limited by the low number of cases and 
the quality of the reports, sometimes originating from posters. 
With the increased prevalence of tattoos among the popula-
tion, tattoo reactions associated with targeted therapies and im-
munotherapies for cancer may become more frequent. Those reac-
tions affect mostly old black tattoos. We cannot rule out that the 
seeming affinity of those reactions to black tattoos is fortuitous. 
Histologically reactions range from lymphocytic infiltration to 
granulomatous reaction. They may be associated with genuine sys-
temic sarcoidosis that should not be mistaken for metastatic pro-
gression [7]. Close monitoring is mandatory, invasive biopsies 
may be necessary if in doubt. Outcome is usually favorable, and 
treatment discontinuation is not obligatory. 
Key Message
The use of immune checkpoint inhibitors and targeted thera-
pies for advanced cancers may lead to granulomatous reactions 
and sarcoidosis within tattoos.
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